

# Deacon's Challenge

## No 128 - Answer

A newly diagnosed epileptic commenced treatment with a daily oral phenytoin dose of 150 mg. After 2 months of treatment his average steady state plasma phenytoin concentration was 4.1 mg/L. Since there had been little clinical improvement the dose was increased to 200 mg per day and after a further 2 month period the new plasma phenytoin concentration was 7.5 mg/L. However, seizure control was still not ideal and the Neurologist has asked you to calculate the expected plasma phenytoin concentration if the dose is further increased to 250 mg. Assume that phenytoin clearance follows saturation kinetics and bioavailability,  $F = 1$ , salt conversion factor,  $S = 0.92$  and the dosing interval,  $\tau = 24$  h.

Phenytoin is metabolised by hepatic oxidases which may become saturated. Therefore the rate of metabolism is non-linearly related to dose and mirrors the Michaelis-Menten equation used in enzyme kinetics:

$$v = \frac{V_{\max} [s]}{K_m + [s]}$$

In a steady state,  $[s]$  = average plasma concentration of the drug,  $C_{ss}$ , and the rate of metabolism must be equal to the rate of administration, which is given by  $F \times S \times \text{Dose}/\tau$ . Substituting these into the Michaelis-Menten equation gives the useful expression:

$$\frac{F \times S \times \text{Dose}}{\tau} = \frac{V_{\max} C_{ss}}{K_m + C_{ss}}$$

Calculation of the plasma steady state concentration when the dose is increased to 250 mg requires knowledge of the constants  $F$ ,  $S$ ,  $K_m$  and  $V_{\max}$ . Only the first two are given but values for  $K_m$  and  $V_{\max}$  can be calculated from the two simultaneous equations which results when two pairs of values for dose and  $C_{ss}$  are substituted into the above equation. For simplicity it is best to work with one of the linear transformations of the Michaelis-Menten equation (it doesn't matter which one). The double reciprocal transformation of Lineweaver & Burk gives the following equation:

$$\frac{\tau}{F \times S \times \text{Dose}} = \frac{K_m}{V_{\max} C_{ss}} + \frac{1}{V_{\max}}$$

When dose = 150 mg,  $C_{ss} = 4.1$  mg/L, therefore

$$\frac{24}{1 \times 0.92 \times 150} = \frac{K_m}{4.1 V_{\max}} + \frac{1}{V_{\max}}$$

ACB News | Issue 585 | January 2012

Practice FRCPATH Style Calculations | 7

and when dose = 200 mg,  $C_{ss} = 7.5$  mg/L

$$\frac{24}{1 \times 0.92 \times 200} = \frac{K_m}{7.5 V_{\max}} + \frac{1}{V_{\max}}$$

Simplifying these two equations:

$$0.174 = \frac{0.244 K_m}{V_{\max}} + \frac{1}{V_{\max}}$$

and

$$0.130 = \frac{0.133 K_m}{V_{\max}} + \frac{1}{V_{\max}}$$

Subtraction of the second equation from the first eliminates the  $1/V_{\max}$  term:

$$0.044 = 0.111 K_m / V_{\max}$$

Therefore  $K_m / V_{\max} = \frac{0.044}{0.111} = 0.396$

Substitute this value for  $K_m / V_{\max}$  into one of the simultaneous equations (it doesn't matter which) and solve for  $V_{\max}$ . Using the first equation:

$$0.174 = 0.244 \times 0.396 + \frac{1}{V_{\max}}$$

$$\frac{1}{V_{\max}} = 0.174 - (0.244 \times 0.396) = 0.174 - 0.0966 = 0.0774$$

$$V_{\max} = 1/0.0774 = 12.9 \text{ mg/h/L}$$

Substitute this value into  $K_m / V_{\max} = 0.396$  and solve for  $K_m$ :

$$\frac{K_m}{12.9} = 0.396$$

$$K_m = 0.396 \times 12.9 = 5.1 \text{ mg/L}$$

To calculate the plasma concentration at the new dose of 250 mg substitute dose = 250 mg,  $F = 1$ ,  $S = 0.92$ ,  $\tau = 24$  h,  $K_m = 5.1$  mg/L and  $V_{\max} = 12.9$  mg/h/L into the Michaelis-Menten equation, and solve for the  $C_{ss}$  term:

$$\begin{aligned} \frac{1 \times 0.92 \times 250}{24} &= \frac{12.9 \times C_{ss}}{5.1 + C_{ss}} \\ 9.58 &= \frac{12.9 \times C_{ss}}{5.1 + C_{ss}} \\ 9.58 (5.1 + C_{ss}) &= 12.9 \times C_{ss} \\ 48.9 + 9.58 C_{ss} &= 12.9 \times C_{ss} \\ 12.9 C_{ss} - 9.58 C_{ss} &= 48.9 \text{ mg/L} \end{aligned}$$

Issue 585 | January 2012 | ACB News

8 | Practice FRCPATH Style Calculations

$$\begin{aligned} 3.32 C_{ss} &= 48.9 \text{ mg/L} \\ C_{ss} &= \frac{48.9}{3.32} = 15 \text{ mg/L (to 2 sig figs)} \end{aligned}$$

Note that as metabolism becomes saturated a relatively small increase in phenytoin dose results in a marked increase in plasma concentration. ■

## Question 129

A 22 year old man (body weight 75 Kg) was referred to a Neurologist by his GP with a history of 8 seizures over the previous 3 months. He was previously successfully treated for grand mal epilepsy for many years with sodium phenytoin 100 mg bd. After obtaining a trough plasma phenytoin level of 8 mg/L the Neurologist increased the dose to 150 mg bd. However, the patient misunderstood the Neurologist's instructions and continued to take his old tablets in addition to his new dose (so that he was actually taking 250 mg bd). Over the next few weeks he became increasingly unwell, complaining of tiredness, nausea and vomiting. In A&E nystagmus was noted, a plasma phenytoin level 130 mg/L confirmed phenytoin toxicity and medication was stopped immediately. The Neurologist has asked you to estimate how long it will take for the plasma level to return to the relatively safe concentration of 10 mg/L by endogenous clearance alone, at which point medication will be resumed.

Assume a volume of distribution of 0.65 L/Kg, normal renal and hepatic function and that phenytoin clearance follows saturation kinetics. Using the direct linear plot of Mullen to evaluate previous data, his  $K_m$  was estimated at 5.0 mg/L and  $V_{\max}$  at 312 mg/24 h total vol.

**www.cityassays.org.uk**

### Thiopurine Metabolites

Whole blood 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine (6-MMPN)

This assay is increasingly requested in patients being treated with thiopurine drugs especially in:

- Treating patients with a low TGMT activity
- Suspecting non-compliance
- Failure to respond to standard doses of drugs

For further information contact: info@cityassays.org.uk or visit www.cityassays.org.uk

Price: £29

Turn round target: 2 working days

Address for samples: Clinical Biochemistry City Hospital Dudley Road Birmingham B18 7QH

Sandwell and West Birmingham Hospitals NHS Foundation Trust

ACB News | Issue 585 | January 2012